Recently, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become a recommended therapy for people with T2D and CKD and are recommended as a risk-based treatment to improve glucose control, weight loss and cardiovascular risk management in this population [11–13]. Here, GLP1R is linked to type 2 diabetes mellitus.